These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Glucose targets for preventing diabetic kidney disease and its progression. Ruospo M; Saglimbene VM; Palmer SC; De Cosmo S; Pacilli A; Lamacchia O; Cignarelli M; Fioretto P; Vecchio M; Craig JC; Strippoli GF Cochrane Database Syst Rev; 2017 Jun; 6(6):CD010137. PubMed ID: 28594069 [TBL] [Abstract][Full Text] [Related]
31. Interventions for BK virus infection in kidney transplant recipients. Wajih Z; Karpe KM; Walters GD Cochrane Database Syst Rev; 2024 Oct; 10(10):CD013344. PubMed ID: 39382091 [TBL] [Abstract][Full Text] [Related]
32. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Piechotta V; Iannizzi C; Chai KL; Valk SJ; Kimber C; Dorando E; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2021 May; 5(5):CD013600. PubMed ID: 34013969 [TBL] [Abstract][Full Text] [Related]
33. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cooper TE; Teng C; Tunnicliffe DJ; Cashmore BA; Strippoli GF Cochrane Database Syst Rev; 2023 Jul; 7(7):CD007751. PubMed ID: 37466151 [TBL] [Abstract][Full Text] [Related]
34. Upper limb exercise for arteriovenous fistula maturation in people requiring permanent haemodialysis access. Nantakool S; Reanpang T; Prasannarong M; Pongtam S; Rerkasem K Cochrane Database Syst Rev; 2022 Oct; 10(10):CD013327. PubMed ID: 36184076 [TBL] [Abstract][Full Text] [Related]
35. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878 [TBL] [Abstract][Full Text] [Related]
36. Interventions for weight loss in people with chronic kidney disease who are overweight or obese. Conley MM; McFarlane CM; Johnson DW; Kelly JT; Campbell KL; MacLaughlin HL Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013119. PubMed ID: 33782940 [TBL] [Abstract][Full Text] [Related]
37. Pharmacological interventions for heart failure in people with chronic kidney disease. Lunney M; Ruospo M; Natale P; Quinn RR; Ronksley PE; Konstantinidis I; Palmer SC; Tonelli M; Strippoli GF; Ravani P Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012466. PubMed ID: 32103487 [TBL] [Abstract][Full Text] [Related]
38. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959 [TBL] [Abstract][Full Text] [Related]
39. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244 [TBL] [Abstract][Full Text] [Related]